Author of

• 11543

  +

  P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11584

    +

    P2.06-041 - Plasma Vascular endothelial growth factor 165(VEGF 165) in advanced Non-small cell lung cancer (ID 2927)

    09:30 - 09:30  |  Author(s): A. El Bastawisy
    • Abstract

    Background
    Lung cancer is the leading cause of death among malignant tumors worldwide therefore it is important to develop novel diagnostic techniques.

    Methods
    This is a prospective case control study including two groups of patients: Group I: healthy volunteers as control .Group II: Patients with advanced non-small cell lung cancer (NSCLC). Plasma VEGF 165 levels were measured at baseline by ELISA before first line Gemcitabine-Cisplatin regimen. High VEGF 165 cutoff taken was >703 pg/ml .Primary end point was comparison of plasma VEGF 165 levels in cases and controls. Secondary endpoint was correlation between High VEGF 165 and clinical response (CR), Progression free survival (PFS) and overall survival (OS) in advanced NSCLC patients.

    Results
    35 patients with advanced NSCLC and 34 age and sex matched normal subjects as control were included and followed up during the period from 10/2009 to 10/2012 with median follow up of 10.5 months. Median plasma VEGF 165 level was 707 pg./ml in cases versus 48 pg./ml in controls, (p < 0.001).No significant correlation was found between plasma VEGF 165 level and clinical response(p < 0.5).No significant correlation was found between plasma VEGF 165 level and Median PFS and OS (p=1 and 0.7 respectively.

    Conclusion
    Plasma VEGF 165 is a potential diagnostic marker in advanced NSCLS.

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12487

    +

    P3.06-047 - Prognostic value of neutrophil lymphocyte ratio in second line advanced malignant pleural mesothelioma (ID 3135)

    09:30 - 09:30  |  Author(s): A. El Bastawisy
    • Abstract

    Background
    Malignant pleural mesothelioma is a lethal disease and hence the strong need for identifying new prognostic factors.

    Methods
    This is a retrospective study including all eligible patients with advanced malignant pleural mesothelioma (MPM) presenting to National Cancer Institute, Cairo University. Neutrophil lymphocyte (N/L) ratio was assessed before second line chemotherapy.2.5 was used as the cutoff point. Endpoints were assessment of correlation between N/L ratio and clinical response (CR), progression free survival (PFS) and overall survival (OS).

    Results
    52 patients (19 stage III and 33 stage IV) MPM were included and followed up during the period from July 2009 till November 2012 with a median follow up period of 2.6 months. 87.5% of patients with N/L ratio > 2.5 showed progressive disease versus 91.7% in patients with N/L ratio <2.5. (P-value=0.66).6 months PFS was 11% for patients with N/L ratio > 2.5 versus 14% for patients with N/L ratio <2.5. (P-value =0.001). 6 months OS was 72% for patients with N/L ratio > 2.5 versus 66% for patients with N/L ratio <2.5. (P-value =0.4).

    Conclusion
    N/L ratio is a potential prognostic marker for advanced MPM treated with second line chemotherapy.